The historical rank and industry rank for IRLAB Therapeutics AB's Net Margin % or its related term are showing as below:
OSTO:IRLAB A'
s Net Margin % Range Over the Past 10 Years
Min: -411661.11 Med: -16391.04 Max: 5781.48
Current: -2770.38
OSTO:IRLAB A's Net Margin % is ranked worse than 83.25% of 1027
companies
in the Biotechnology industry
Industry Median: -154.15
vs OSTO:IRLAB A: -2770.38
IRLAB Therapeutics AB Net Margin % Historical Data
The historical data trend for IRLAB Therapeutics AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IRLAB Therapeutics AB's Net Margin %
For the Biotechnology subindustry, IRLAB Therapeutics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's Net Margin % falls into.
IRLAB Therapeutics AB Net Margin % Calculation
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
IRLAB Therapeutics AB's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IRLAB Therapeutics AB (OSTO:IRLAB A) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
IRLAB Therapeutics AB Net Margin % Related Terms
Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:IRLAB A has been successfully added to your 